vs
Side-by-side financial comparison of BCB BANCORP INC (BCBP) and Invivyd, Inc. (IVVD). Click either name above to swap in a different company.
BCB BANCORP INC is the larger business by last-quarter revenue ($26.2M vs $17.2M, roughly 1.5× Invivyd, Inc.). BCB BANCORP INC runs the higher net margin — -49.7% vs -64.3%, a 14.7% gap on every dollar of revenue. On growth, Invivyd, Inc. posted the faster year-over-year revenue change (24.5% vs 13.1%).
Invivyd, Inc. is a clinical-stage biopharmaceutical company focused on developing broadly neutralizing antibody therapies to prevent and treat serious viral infectious diseases. Its core research and development pipeline targets high-burden respiratory pathogens including respiratory syncytial virus, catering to unmet medical needs of global patient groups.
BCBP vs IVVD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $26.2M | $17.2M |
| Net Profit | $-12.0M | $-11.1M |
| Gross Margin | — | — |
| Operating Margin | -71.9% | -73.0% |
| Net Margin | -49.7% | -64.3% |
| Revenue YoY | 13.1% | 24.5% |
| Net Profit YoY | -467.6% | 40.0% |
| EPS (diluted) | $-0.73 | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $26.2M | $17.2M | ||
| Q3 25 | $26.5M | $13.1M | ||
| Q2 25 | $25.2M | $11.8M | ||
| Q1 25 | $23.8M | $11.3M | ||
| Q4 24 | $23.1M | $13.8M | ||
| Q3 24 | $26.2M | $9.3M | ||
| Q2 24 | $20.4M | $2.3M | ||
| Q1 24 | $25.3M | $0 |
| Q4 25 | $-12.0M | $-11.1M | ||
| Q3 25 | $4.3M | $-10.5M | ||
| Q2 25 | $3.6M | $-14.7M | ||
| Q1 25 | $-8.3M | $-16.3M | ||
| Q4 24 | $3.3M | $-18.4M | ||
| Q3 24 | $6.7M | $-60.7M | ||
| Q2 24 | $2.8M | $-47.2M | ||
| Q1 24 | $5.9M | $-43.5M |
| Q4 25 | -71.9% | -73.0% | ||
| Q3 25 | 21.9% | -84.0% | ||
| Q2 25 | 19.9% | -127.8% | ||
| Q1 25 | -49.2% | -149.7% | ||
| Q4 24 | 19.9% | -139.1% | ||
| Q3 24 | 35.7% | -670.0% | ||
| Q2 24 | 19.5% | -2175.2% | ||
| Q1 24 | 33.0% | — |
| Q4 25 | -49.7% | -64.3% | ||
| Q3 25 | 16.1% | -79.7% | ||
| Q2 25 | 14.2% | -124.4% | ||
| Q1 25 | -35.0% | -144.1% | ||
| Q4 24 | 14.1% | -133.5% | ||
| Q3 24 | 25.5% | -653.1% | ||
| Q2 24 | 13.8% | -2086.9% | ||
| Q1 24 | 23.2% | — |
| Q4 25 | $-0.73 | $0.02 | ||
| Q3 25 | $0.22 | $-0.06 | ||
| Q2 25 | $0.18 | $-0.12 | ||
| Q1 25 | $-0.51 | $-0.14 | ||
| Q4 24 | $0.17 | $-0.14 | ||
| Q3 24 | $0.36 | $-0.51 | ||
| Q2 24 | $0.14 | $-0.40 | ||
| Q1 24 | $0.32 | $-0.38 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $226.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $304.3M | $241.5M |
| Total Assets | $3.3B | $276.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $226.7M | ||
| Q3 25 | — | $85.0M | ||
| Q2 25 | — | $34.9M | ||
| Q1 25 | — | $48.1M | ||
| Q4 24 | — | $69.3M | ||
| Q3 24 | — | $106.9M | ||
| Q2 24 | — | $147.9M | ||
| Q1 24 | — | $189.4M |
| Q4 25 | $304.3M | $241.5M | ||
| Q3 25 | $318.5M | $93.1M | ||
| Q2 25 | $315.7M | $42.8M | ||
| Q1 25 | $314.7M | $54.1M | ||
| Q4 24 | $323.9M | $67.5M | ||
| Q3 24 | $328.1M | $83.2M | ||
| Q2 24 | $320.7M | $140.6M | ||
| Q1 24 | $320.1M | $178.5M |
| Q4 25 | $3.3B | $276.9M | ||
| Q3 25 | $3.4B | $139.2M | ||
| Q2 25 | $3.4B | $89.1M | ||
| Q1 25 | $3.5B | $103.7M | ||
| Q4 24 | $3.6B | $129.5M | ||
| Q3 24 | $3.6B | $161.9M | ||
| Q2 24 | $3.8B | $177.3M | ||
| Q1 24 | $3.8B | $215.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.9M | $-15.5M |
| Free Cash FlowOCF − Capex | $34.9M | — |
| FCF MarginFCF / Revenue | 133.3% | — |
| Capex IntensityCapex / Revenue | 4.0% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $58.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.9M | $-15.5M | ||
| Q3 25 | $8.7M | $-8.3M | ||
| Q2 25 | $10.3M | $-13.3M | ||
| Q1 25 | $5.0M | $-21.1M | ||
| Q4 24 | $67.7M | $-37.6M | ||
| Q3 24 | $43.5M | $-41.1M | ||
| Q2 24 | $8.1M | $-41.6M | ||
| Q1 24 | $8.3M | $-50.2M |
| Q4 25 | $34.9M | — | ||
| Q3 25 | $8.5M | — | ||
| Q2 25 | $10.2M | $-13.3M | ||
| Q1 25 | $4.7M | $-21.3M | ||
| Q4 24 | $66.5M | $-37.6M | ||
| Q3 24 | $43.4M | $-41.1M | ||
| Q2 24 | $8.1M | — | ||
| Q1 24 | $8.1M | $-50.4M |
| Q4 25 | 133.3% | — | ||
| Q3 25 | 32.0% | — | ||
| Q2 25 | 40.4% | -112.9% | ||
| Q1 25 | 19.8% | -188.2% | ||
| Q4 24 | 287.5% | -272.2% | ||
| Q3 24 | 166.0% | -441.6% | ||
| Q2 24 | 39.6% | — | ||
| Q1 24 | 32.3% | — |
| Q4 25 | 4.0% | 0.0% | ||
| Q3 25 | 1.1% | 0.0% | ||
| Q2 25 | 0.6% | 0.1% | ||
| Q1 25 | 1.2% | 1.3% | ||
| Q4 24 | 5.3% | 0.0% | ||
| Q3 24 | 0.3% | 0.1% | ||
| Q2 24 | 0.2% | 0.0% | ||
| Q1 24 | 0.6% | — |
| Q4 25 | — | — | ||
| Q3 25 | 2.05× | — | ||
| Q2 25 | 2.90× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 20.70× | — | ||
| Q3 24 | 6.53× | — | ||
| Q2 24 | 2.88× | — | ||
| Q1 24 | 1.41× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
